Glenmark Life Sciences IPO to open today: Check all details here

Published on Jul 27, 2021 05:55 AM IST

Glenmark Life Sciences share sale consists of a fresh issue of equities worth ₹1,060 crore and an offer for sale by promoter Glenmark Pharmaceuticals for ₹453 crore.

Glenmark Pharmaceuticals entered API manufacturing in 2001-02 with a facility in Maharashtra's Kurkumbh.(HT File Photo)
Glenmark Pharmaceuticals entered API manufacturing in 2001-02 with a facility in Maharashtra's Kurkumbh.(HT File Photo)
By | Written by Susmita Pakrasi, Hindustan Times, New Delhi

Glenmark Life Sciences IPO will open on Tuesday and conclude on July 29 and the company has fixed a price band of 695-720 a share for its initial share sale. The Glenmark Life Sciences IPO will fetch 1,513.6 crore at the upper end of the price band, news agency PTI reported.

Glenmark Life Sciences share sale consists of a fresh issue of equities worth 1,060 crore and an offer for sale by promoter Glenmark Pharmaceuticals for 453 crore.

HSBC Global Investment Funds, Government Pension Fund Global, Oaktree Emerging Markets Equity Fund LP, Copthall Mauritius Investment Ltd-ODI account, Societe Generale-ODI, Kuber India Fund and Reliance General Insurance Company are among the anchor investors.

The equity shares of the company will be listed on BSE and NSE and the expected date of listing is August 6.

Glenmark Pharmaceuticals shares on Monday settled at 667.90, down 2.05 per cent from the previous close.

Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals, develops and manufactures select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management and diabetes. Glenmark Life Sciences also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas.

Glenmark Pharmaceuticals entered API manufacturing in 2001-02 with a facility in Maharashtra's Kurkumbh. "The capacity expansion is on the back of our plan to enter more regulated growth markets like Brazil, Mexico, Russia, Korea, Taiwan and Saudi Arabia," Glenmark Life Sciences chief executive and managing director Yasir Rawjee told PTI.

SHARE THIS ARTICLE ON
SHARE
Story Saved
×
Saved Articles
Following
My Reads
My Offers
Sign out
New Delhi 0C
Sunday, December 04, 2022
Start 15 Days Free Trial Subscribe Now
Register Free and get Exciting Deals